A recent study indicates that individuals who discontinue blockbuster slimming jabs like semaglutide or tirzepatide may regain lost weight far faster than those who end traditional lifestyle programs.
Findings released in a major health publication shows that while overweight individuals frequently drop substantial amounts of their total mass while using the jabs, the weight comes back at an average rate of nearly a kilo each month after stopping.
"Users using such drugs must be informed of the risk of quick rebound weight gain when the medication ends," stated lead investigator Dr. Susan Jebb.
Such speed of recovery means a reversion to starting mass within about a year and a half.
Comparing Treatments
The study, which examined 37 of studies involving over 9,000 of patients, contrasted the outcomes of the injectable medications with older methods.
Scientists note that people who shed pounds through dieting usually see a more gradual creep back—perhaps 100 grams monthly—once they finish.
Explaining the Rapid Regain
Nutrition scientists suggest the mechanism of the injections accounts for the heightened regain.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing the hormone concentrations several times higher than normal might result in the body to produce less of its own natural hormone, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this hormone supplement means hunger is unsuppressed, making overeating far more likely."
A Lifelong Issue?
The NHS advise the injections for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Professionals argue that, due to the high risk of relapse, the therapy might need to be life-long.
This perspective is reinforced by drug manufacturers, who note that the findings "underscore the chronic nature of obesity," similar to managing diseases like hypertension.
Patient Testimonies
Users who have discontinued the medication report a intense resurgence of hunger.
"It was like a switch that goes on and you become starving," recalled one woman.
This challenge is exacerbated if users have not developed lasting dietary or behavioural modifications during therapy.
Growing Adoption
Figures suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is greater among females than males.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
Ultimately, clinicians caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone cure and maintained weight loss relies on integrated behavioural management.
